Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.
[1][2] that targets IL-23.
[3] This drug was developed by MedImmune.
Immune activation: Dostarlimab Other: Ibalizumab This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.